» Articles » PMID: 35399522

Hematopoietic Stem Cell Factors: Their Functional Role in Self-Renewal and Clinical Aspects

Overview
Specialty Cell Biology
Date 2022 Apr 11
PMID 35399522
Authors
Affiliations
Soon will be listed here.
Abstract

Hematopoietic stem cells (HSCs) possess two important properties such as self-renewal and differentiation. These properties of HSCs are maintained through hematopoiesis. This process gives rise to two subpopulations, long-term and short-term HSCs, which have become a popular convention for treating various hematological disorders. The clinical application of HSCs is bone marrow transplant in patients with aplastic anemia, congenital neutropenia, sickle cell anemia, thalassemia, or replacement of damaged bone marrow in case of chemotherapy. The self-renewal attribute of HSCs ensures long-term hematopoiesis post-transplantation. However, HSCs need to be infused in large numbers to reach their target site and meet the demands since they lose their self-renewal capacity after a few passages. Therefore, a more in-depth understanding of HSCs expansion needs to be developed to delineate ways to enhance the self-renewability of isolated HSCs. The multifaceted self-renewal process is regulated by factors, including transcription factors, miRNAs, and the bone marrow niche. A developed classical hierarchical model that outlines the hematopoiesis in a lineage-specific manner through fate mapping, barcoding, and determination of self-renewal regulatory factors are still to be explored in more detail. Thus, an in-depth study of the self-renewal property of HSCs is essentially required to be utilized for expansion. This review primarily focuses on the Hematopoietic stem cell self-renewal pathway and evaluates the regulatory molecular factors involved in considering a targeted clinical approach in numerous malignancies and outlining gaps in the current knowledge.

Citing Articles

Secretome from HMGB1 Box A-over-expressing Adipose-derived Stem Cells Shows Potential for Skin Rejuvenation by Senescence Reversal in PM2.5-induced Senescence Cells Stem Cell Induction.

Ei Z, Mutirangura A, Chanvorachote P In Vivo. 2025; 39(2):766-777.

PMID: 40010963 PMC: 11884463. DOI: 10.21873/invivo.13881.


Anti-Inflammatory Resveratrol Protects Mice From Early Mortality After Haematopoietic Stem Cell Transplantation.

Zhang X, Yu W, Sun Y, Ye X, He Y, Huang X J Cell Mol Med. 2025; 29(3):e70395.

PMID: 39900564 PMC: 11790355. DOI: 10.1111/jcmm.70395.


Differentiation ability of hematopoietic stem cells and mesenchymal stem cells isolated from human peripheral blood.

Samundeshwari E, Kattaru S, Kodavala S, Chandrasekhar C, Sarma P Front Cell Dev Biol. 2025; 12:1450543.

PMID: 39744010 PMC: 11688275. DOI: 10.3389/fcell.2024.1450543.


Unlocking the regenerative key: Targeting stem cell factors for bone renewal.

Karima G, Kim H J Tissue Eng. 2024; 15:20417314241287491.

PMID: 39479284 PMC: 11523181. DOI: 10.1177/20417314241287491.


Exploring the contribution of Zfp521/ZNF521 on primary hematopoietic stem/progenitor cells and leukemia progression.

Chiarella E Cell Tissue Res. 2024; 398(3):161-173.

PMID: 39436449 PMC: 11614986. DOI: 10.1007/s00441-024-03926-2.


References
1.
Gao J, Chen Y, Peterson L . GATA family transcriptional factors: emerging suspects in hematologic disorders. Exp Hematol Oncol. 2015; 4:28. PMC: 4594744. DOI: 10.1186/s40164-015-0024-z. View

2.
Fukushima T, Miyazaki Y, Tsushima H, Tsutsumi C, Taguchi J, Yoshida S . The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. Leuk Res. 2003; 27(5):387-92. DOI: 10.1016/s0145-2126(02)00214-x. View

3.
Schmidt T, Karsunky H, Rodel B, Zevnik B, Elsasser H, Moroy T . Evidence implicating Gfi-1 and Pim-1 in pre-T-cell differentiation steps associated with beta-selection. EMBO J. 1998; 17(18):5349-59. PMC: 1170861. DOI: 10.1093/emboj/17.18.5349. View

4.
Bhatlekar S, Fields J, Boman B . Role of HOX Genes in Stem Cell Differentiation and Cancer. Stem Cells Int. 2018; 2018:3569493. PMC: 6081605. DOI: 10.1155/2018/3569493. View

5.
Osato M . Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004; 23(24):4284-96. DOI: 10.1038/sj.onc.1207779. View